It is printed in the A4 size.To the laboratory site

 - Clinical Medicine (Core Departments)
Transfusion Medicine and Cell Therapy
Former department was fully restructured in 2002 as a new Department of Transfusion Medicine and Cell Therapy along with the rapid progress of medicinal science elucidating new molecular and cellular pathophysiology of incurable diseases such as cancers. In addition to control transfusion therapy in the hospital, we supply purified hematopoietic stem cells and relevant cells to clinical trials for allogeneic bone marrow, peripheral blood, and cord blood transplantations. Our research and clinical goals are to develop innovative cell therapy, regenerative therapy, and molecular target therapy for leukemias and other malignancies. Stem cell transplantation, cell and regenerative therapy, and molecular target therapy being ultimate therapeutic approaches for incurable diseases, their establishments (translational research) are urgently needed. To provide clinical-graded therapeutic human cells for translational trials, GMP-graded cell processing facility (Center for Cell and Molecular Therapy: CCMT, Fig.1) has been established in 2003 next door to the Department. Therefore, the Department of Transfusion Medicine and Cell Therapy will play the pivotal role in new era for the progress of advanced medical research and clinical trials at Kyoto University Hospital.

  Taira Maekawa, M.D., D.Med. Sci.
Research and Education
This department is responsible for education concerning transfusion medicine for undergraduate and graduate students, and also has to supervise appropriate use of blood products for transfusion therapy in the university hospital. In addition, to improve the clinical outcome of hematopoietic stem cell transplantation and cell therapy, we provide qualified and powerful therapeutic human cells and tissues to the clinical settings and develop novel method to detect anti-ABO, and anti-HLA antibodies (Fig 2). Recently we have successfully performed allogeneic islet cell transplantation to a patient with severe type I diabetes from a related living donor for the first time in the world. In addition to these cellular therapies, we have been engaged in basic and clinical researches involving molecular target therapy for cancer. We are now working on the following three main projects; a) imatinib mesylate, a competitive inhibitor of Abl tyrosine kinase, is highly effective, but remissions induced in advanced phase CML and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia tend to be relatively short-lived mostly due to point mutations within the Abl kinase domain. New tyrosine kinase inhibitors have been developed to override such resistance. We developed INNO-406, which is one of these new compounds and phase I clinical trial has been successfully, and has named bafetinib and multi-kinase inhibitor, AT9283 (Fig.3) , b) RNA interference, which has recently been introduced into cancer therapy, is a newly discovered cellular pathway for silencing genes at the mRNA level in a sequence-specific manner by the introduction of small interfering RNA (siRNA)(Fig.4), c) γδT cells kill myeloma cells by recognizing metabolites of the mevalonate pathway and ICAM-1 on the myeloma cells. This suggests that patients with myeloma cells that express high levels of ICAM-1 are suitable for cellular immunotherapy usingγδT cells in a clinical setting (Fig.5). We are also interested in the transcriptional system of granulopoiesis and in the control of GvHD using mesenchymal stem cells, and trying to bring it into translational research. Young investigators and graduate students with curious and challenging mind are always very welcome (Fig.6).

Transfusion Medicine and Cell Therapy
Professor Taira Maekawa

Hideyo Hirai

Yasuo Miura
TEL +81-75-751-3628
FAX +81-75-751-3631
Cell processing for cultured mesenchymal stem cells at CCMT
Novel method using surface plasmon resonance to detect anti-A/B antibodies
News release of novel multi-kinase inhibitor for CML
PLK-1 siRNA inhibits progression of liver metastasis in lung cancers
gamma delta T cells (small) attack malignant cells (large)
Colleagues of the department
Recent Publications
1. Takeuchi M et al. (2011) Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr-Abl positive leukemic cells. Cancer Sci, in press.
2. Tanaka R et al. (2010) Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL positive leukemic cells. Blood 116(12):2089-95.
3. Takeuchi M et al. (2010) Glyoxalase-I induction during hypoxia adaptation in Bcr-Abl positive leukaemic cells. Cell Death Diff 17:1211-1220.
4. Ashihara E et al. (2010) Future Prospect of RNA interference for cancer therapies. Curr Drug Targets. 11(3): 345-360, 2010.
5. Ashihara E et al. (2009) Beta-catenin siRNA successfully suppressed progression of multiple myeloma in a mouse model. Clin Cancer Res, 15:2731-2738.
6. Yokota A et al (2007) INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system and cyclosporine A augments its in vivo activity. Blood, 109:306-314
7. Hirai H et al(2006) C/EBPbeta is required for emergency granulopoiesis. Nat Immunol. 7:732-739.